lobbying_activities: 794333

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
794333	31753018-5dcf-4e63-8003-561f638953f8	Q2	TEVA PHARMACEUTICALS USA, INC.	76695	TEVA PHARMACEUTICALS USA INC	2009	second_quarter	PHA	S. 301, Physician Payments Sunshine Act of 2009; H.R. 1859 and S. 767, Independent Drug Education and Outreach Act of 2009; H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicine Act; and H.R. 1548, Pathway for Biosimilars Act; legislation and proposals relating to "doughnut hole" impact; and FDA implementation of the Food & Drug Administration Amendments Act ("FDAAA").	Commerce, Dept of (DOC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Patent & Trademark Office (PTO),SENATE,U.S. Trade Representative (USTR)		840000	0	0	2009-07-16T16:48:42-04:00